Publications by authors named "Julia A Schulz"
The drug efflux transporters ABCB1 and ABCG2 at the blood-brain barrier limit the delivery of drugs into the brain. Strategies to overcome ABCB1/ABCG2 have been largely unsuccessful, which poses a tremendous clinical problem to successfully treat central nervous system (CNS) diseases. Understanding basic transporter biology, including intracellular regulation mechanisms that control these transporters, is critical to solving this clinical problem.
View Article and Find Full Text PDFAccording to the free drug hypothesis (FDH), only free, unbound drug is available to interact with biological targets. This hypothesis is the fundamental principle that continues to explain the vast majority of all pharmacokinetic and pharmacodynamic processes. Under the FDH, the free drug concentration at the target site is considered the driver of pharmacodynamic activity and pharmacokinetic processes.
View Article and Find Full Text PDFArticle Synopsis
- Glioblastoma (GBM) is a highly aggressive cancer with limited treatment options and a median survival of just a few months.
- Researchers characterized two GBM cell lines, U87-luc2 and U251-RedFLuc, which show similar lab responses but exhibit different tumor growth patterns in vivo—U87-luc2 forms large tumors while U251-RedFLuc creates small, invasive tumors.
- The study introduces a new method for assessing tumor invasiveness and reveals that U251-RedFLuc is more invasive than U87-luc2, highlighting the importance of recognizing the different characteristics of these models in GBM research.
Article Synopsis
- * Studying the human BBB is difficult, leading to a need for models that accurately represent its function, such as isolated brain capillaries from human tissue.
- * The article presents a protocol for isolating these capillaries and highlights their use in experiments to investigate BBB function, offering potential insights for treating central nervous system disorders.